Ixazomib – the first oral proteasome inhibitor. Issue 3 (23rd February 2019)

• Record Type: Journal Article
• Authors: Xie, Jingmei; Wan, Ning; Liang, Zhuoru; Zhang, Tiantian; Jiang, Jie
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 3(2019)
• Page Start: 610
• Page End: 618
• Publication Date: 2019-02-23
• Subjects: Ixazomib -- relapsed/refractory multiple myeloma -- proteasome inhibitor; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1523398
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study, ixazomib was proved by the FDA as the orphan drug in November 2015. With a promising effect in prolonging the progression-free survival compared with placebo treatment (median: 20.6 versus 14.7 months), it was the first oral compound combined with lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. The main adverse events include low-grade hematological, digestive, or cutaneous events, which were manageable with care. Overall, ixazomib demonstrated favorable safety profile. Ongoing trials are conducted to define its place in first-line, maintenance, and relapse therapies. In this review, we summarized the clinical pharmacology, efficacy, tolerability, safety, and cost-effectiveness of ixazomib.